Preventing trogocytosis by cathepsin B inhibition augments CAR T cell function
Authors:
- Kenneth A. DietzeKDKenneth A. Dietze
- Aashli PathniAPAashli Pathni
- Frank FazekasFFFrank Fazekas
- Jillian M. BakerJBJillian M. Baker
- Maday Galeana FigueroaMFMaday Galeana Figueroa
- Daniel YamoahDYDaniel Yamoah
- Rediet MulatuRMRediet Mulatu
Preprint
Abstract
Chimeric antigen receptor (CAR) T cell therapy has shown remarkable efficacy in cancer treatment. Still, most patients receiving CAR T cells relapse within 5 years of treatment. CAR-mediated trogocytosis (CMT) is a potential tumor escape mechanism in which cell surface proteins transfer from tumor cells to CAR T cells. CMT results in the emergence of antigen-negative tumor cells, which can evade future CAR detection, and antigen-positive CAR T cells, which is hypothesized to lead to CAR T cell fratricide and dysfunction. Using a system to selectively degrade trogocytosed antigen in CAR T cells, we show that the presence of trogocytosed antigen in CAR T cells directly causes CAR T cell fratricide and exhaustion. By performing a small molecule screening using a custom high throughput CMT-screening assay, we identified the cysteine protease cathepsin B (CTSB) as a key driver of CMT. We show that overexpression of cystatin A (CSTA), an endogenous human inhibitor of CTSB, reduces trogocytosis resulting in prolonged antitumor activity and increased CAR T cell expansion/persistence. Overall, we show that targeting CMT is an effective approach to enhance CAR T cell function, which may improve their clinical efficacy. One sentence summary CAR-mediated trogocytosis directly causes CAR T cell exhaustion and fratricide but can be prevented by inhibiting the cysteine protease cathepsin B through overexpression of human cystatins.Keywords
All Related Versions
- Published version: Signal Transduction and Targeted Therapy, 11 (1), 149.
This publication has 73 references indexed in Scilit:
- Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicityOncoImmunology, 2013
- Correlation Functions Quantify Super-Resolution Images and Estimate Apparent Clustering Due to Over-CountingPLOS ONE, 2012
- Capture of Target Cell Membrane Components via Trogocytosis Is Triggered by a Selected Set of Surface Molecules on T or B CellsThe Journal of Immunology, 2007
- Grafting of Features of Cystatins C or B into the N-Terminal Region or Second Binding Loop of Cystatin A (Stefin A) Substantially Enhances Inhibition of Cysteine ProteinasesBiochemistry, 2003
- Surface Cathepsin B Protects Cytotoxic Lymphocytes from Self-destruction after DegranulationJournal of Experimental Medicine, 2002
- Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop. Demonstration by release of loop anchoring through mutation of His110FEBS Letters, 2000
- The Role of Gly-4 of Human Cystatin A (Stefin A) in the Binding of Target Proteinases. Characterization by Kinetic and Equilibrium Methods of the Interactions of Cystatin A Gly-4 Mutants with Papain, Cathepsin B, and Cathepsin LBiochemistry, 1998
- Cathepsin BThe International Journal of Biochemistry & Cell Biology, 1997
- Novel epoxysuccinyl peptides A selective inhibitor of cathepsin B, in vivoFEBS Letters, 1991
- Novel epoxysuccinyl peptides Selective inhibitors of cathepsin B, in vitroFEBS Letters, 1991